Form D To Observe: Regenerx Biopharmaceuticals $4.38 million Financing. JJ Finkelstein Filed Jul 13 SEC Filing


Pharmaceuticals Regenerx Biopharmaceuticals Inc - JJ Finkelstein

Regenerx Biopharmaceuticals Financing

Regenerx Biopharmaceuticals Inc, Corporation just filed form D about $4.38 million equity financing. This is a new filing. Regenerx Biopharmaceuticals was able to finance itself with $4.38 million. That is 100.00% of the fundraising. The total financing amount was $4.38 million. The private financing document was filed on 2016-07-13. The reason for the financing was: The total offering amount and total amount sold include both common stock and warrants to purchase $2,625,000 of common stock..

Regenerx Biopharmaceuticals is based in Maryland. The firm’s business is Pharmaceuticals. The form was submitted by JJ Finkelstein Chief Executive Officer. The company was incorporated more than five years ago. The filler’s address is: 15245 Shady Grove Road, Suite 470, Rockville, Md, Maryland, 20850. J.J. Finkelstein is the related person in the form and it has address: 15245 Shady Grove Road, Suite 470, Rockville, Md, Maryland, 20850. Link to Regenerx Biopharmaceuticals Filing: 000120919116132613.

Analysis of Regenerx Biopharmaceuticals Offering

On average, firms in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Regenerx Biopharmaceuticals sold 100.00% of the offering. Could this mean that the trust in Regenerx Biopharmaceuticals is high? The average offering amount for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 686.87% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Regenerx Biopharmaceuticals Also

The Form D signed by JJ Finkelstein might help Regenerx Biopharmaceuticals Inc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply